| תיאור כללי: |
(Proposal due 5.9, LOI due 2 weeks prior)
ADDF funds 4 categories of research; drug discovery and preclinical development, early detection, clinical trials and prevention. ADDF does not fund basic research. ADDF is interested in novel targets and therapeutic approaches for Alzheimer’s Disease (AD), related dementias and cognitive aging. These areas include, but are not limited to: Energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury, the blood-brain barrier interface, and translatable biomarkers. ADDF has limited interest in funding anti-amyloid approaches and has limited interest in funding cholinesterase inhibitor programs. Funding priorities: Early identification; Prevention of AD and cognitive decline; Treatment of AD and cognitive aging.
* Repurposing Drugs for AD and Related Dementias Including: phase I-II human clinical trials, animal model studies and other preclinical development work required to bring a repurposed drug into human clinical testing for AD or related dementia. Funding: $100K - $1.5M.
* Preclinical Drug Discovery: ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to AD, other dementias and cognitive aging. ADDF typically supports one year of research at a time, with potential for future follow-on funding. Funding averages $150K/year. In some cases, multi-year proposals can be considered.
* Program to Accelerate Clinical Trials: funding for up to $1.5M per application, is offered to increase the number of innovative drugs tested in humans for AD, related dementias and cognitive aging. This program will fund biomarker-based pilot clinical trials for AD and in some cases will also support Phase I safety testing and IND-enabling studies to accelerate new drugs into trials. ADDF is also interested in supporting targeted pharmacological and non pharmacological approaches to prevention and clinical biomarker development programs. Areas of particular interest include:
- Repurposing: testing drugs approved for other indications in AD clinical trials.
- Therapies addressing the following targets: energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury and the blood-brain barrier interface.
* ADDF/NIH: financial assistance for relevant NIA and NINDS grant applications that were scored but not funded AND fall within the ADDF’s current funding priorities (Application deadline is rolling)
* ADDF/ADCS BIOMARKER-BASED TARGET ENGAGEMENT STUDIES to SUPPORT CLINICAL DEVELOPMENT of NOVEL THERAPEUTICS for ALZHEIMER'S DISEASE: Support for pilot biomarker-based clinical trials of novel therapeutics for Alzheimer's disease. Highest priority: therapeutics which target engagement can be directly assessed in humans using serial cerebrospinal fluid sampling. The proposed study can augment an existing study or be a new pilot clinical trial.
* ADDF/AFTD Accelerating DRUG DISCOVERY for Frontotemporal Degeneration: Aim: accelerate and support drug discovery for FTD and related disorders (NOT basic research). Priority areas include:
-Development of clinical, biochemical, or neuroimaging biomarkers to accelerate drug development and early diagnosis
-High throughput screening in novel cellular assays relevant to FTD
-Identification and in vitro testing of potentially disease modifying compounds or biologics, including medicinal chemistry refinement, ADME, toxicology, pharmacokinetics, and pharmacodynamics studies
-Testing of lead compounds or biologics in a relevant model for preclinical proof of concept
Funding: up to $150K for 1 yr, with possibility of follow-on funding
PLEASE NOTE: THIS FUNDING WILL NOT SUPPORT APPLICATIONS FOR BASIC RESEARCH
http://www.alzdiscovery.org/research-and-grants/request-for-proposal
|
